Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EC vs TC in Elderly Early Breast Cancer
NCT01301040Phase 2Terminated
- Sponsor
- Institut Jules Bordet
- Start
- Mar 2011
- Primary completion
- Mar 2013
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of epirubicin, docetaxel in breast cancer, sponsored by Institut Jules Bordet. Started Mar 2011; status: terminated.
02
Drugs
epirubicindocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01301040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01301040.